Is GenSight Biologics S.A. (GSGTF) a Buy, Sell, or Hold?
OTC : GSGTF
GenSight Biologics S.A.
$0.09 USD
$0 (0.0%)
- Volume
- 756
- Average Volume
- 6
- Market Capitalization
- $14.67M
- P/E Ratio
- -1.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.48
- Year Low
- $0.09
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.39
Company Overview
OTC
Laurence Rodriguez
Biotechnology
Healthcare
GSGTF
13
FR
USD
Liquidity Metrics
-0.52
0.39
0.39
0.19
0.00
Sales & Valuation
$999.63
13235.60
-0.62
-1.44
-0.05
Profitability
-$0.0812
-$12.03M
-1203600.00%
-1204000.00%
42.20%
-145.78%
P/E Metrics
-1.00
-0.02
-0.02
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-12.06
2/9
-$7.68M
$8.25M
$33.19M
-$23.3M
Key Metrics (TTM)
$23.77M
23765.10
-2.11
0.39
42.20%
1515.43%
-77.89%
-68.81%
575605 days
Company Executives
| Name | Title |
|---|---|
| Fang Li | Chief Regulatory & Quality Officer |
| Magali Taiël | Chief Medical Officer |
| Scott Jeffers | Chief Technical Officer |
| Laurence Rodriguez | Chief Executive Officer & Director |
| Marion Ghibaudo | Chief Technical Officer of Medical Device |
| Jose-Alain Sahel | Scientific Founder, Vice Chairman of Scientific Advisory Board & Director |
| Serge Picaud | Scientific Founder & Member of Scientific Advisory Board |
| Julio Benedicto | Senior Vice President of Strategy & Operations |
| Botond Roska | Scientific Founder & Chairman of Scientific Advisory Board |
| Jan Eryk Umiastowski | Chief Financial Officer |
| Barrett Katz | Consultant |
Poll Results
No votes yet today — be the first to share your view!
About GenSight Biologics S.A. (OTC:GSGTF) Stock
GenSight Biologics S.A. is a clinical-stage biotechnology firm dedicated to pioneering, advancing, and bringing to market treatments for serious eye and central nervous system disorders, specifically those linked to mitochondrial dysfunction and neurodegeneration. Their therapeutic pipeline is built upon cutting-edge gene therapy approaches, including mitochondrial targeting sequences and optogenetics technologies. The company's primary drug candidate, LUMEVOQ (GS010), is a recombinant AAV2-based gene therapy currently undergoing Phase III clinical evaluation for Leber hereditary optic neuropathy (LHON) stemming from a specific ND4 gene mutation. Another key candidate, GS030, is in Phase I/II trials for retinitis pigmentosa and is also being investigated in preclinical studies for dry age- ... related macular degeneration. Beyond these, GenSight is also advancing a range of other preclinical programs aimed at addressing various ophthalmic and neurodegenerative conditions. Established in 2012, GenSight Biologics S.A. operates from its headquarters in Paris, France.
GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates
2026-07-08 13:11:00
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of June 30, 2026, and provided business updates. Cash Position as of June 30, 2026 GenSight Biologics' cash and cash equivalents totaled €1.7 million as of June 30, 2026, compared t.
GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026
2026-05-20 12:00:00
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that all 28 resolutions submitted for shareholders' vote at the Combined Shareholders' Meeting held on May 19, 2026, and chaired by Laurence Rodriguez, Chief Executive Officer of the Company, were approved.
GenSight Biologics to Hold its Combined General Meeting on May 19, 2026
2026-05-18 12:30:00
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (the “Company”) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that its Combined General Meeting will be held tomorrow, Tuesday, May 19, 2026, at 2:00 p.m. CEST and will be broadcast live via the following link: GENSIGHT BIOLOGICS - Assembl.
2026-05-11 12:30:00
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of a Matching Adjusted Indirect Comparison (MAIC) of outcomes from the clinical trials of GS010/LUMEVOQ®, the Company's gene therapy investigational product for the treatment of ND4-LHO.
GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026
2026-04-28 14:35:00
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 19, 2026, at 2:00 pm CEST at the Company's headquarters at 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. The General Meeting will also be webcast.
Frequently Asked Questions
-
What is the current GenSight Biologics S.A. (GSGTF) stock price?
-
GenSight Biologics S.A.(OTC:GSGTF) stock price is $0.09 in the last trading session. During the trading session, GSGTF stock reached the peak price of $0.48 while $0.09 was the lowest point it dropped to. The percentage change in GSGTF stock occurred in the recent session was 0.0% while the dollar amount for the price change in GSGTF stock was $0.
-
GSGTF's industry and sector of operation?
-
The OTC listed GSGTF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GSGTF?
-
Fang Li | Chief Regulatory & Quality Officer
Magali Taiël | Chief Medical Officer
Scott Jeffers | Chief Technical Officer
Laurence Rodriguez | Chief Executive Officer & Director
Marion Ghibaudo | Chief Technical Officer of Medical Device -
How many employees does GSGTF have?
-
Number of GSGTF employees currently stands at 13. GSGTF operates from 74, rue du Faubourg Saint-Antoine, Paris, IF 75012, FR.
-
Link for GSGTF official website?
-
Official Website of GSGTF is: https://www.gensight-biologics.com
-
How do I contact GSGTF?
-
GSGTF could be contacted at phone #33 1 76 21 72 20 and can also be accessed through its website. GSGTF operates from 74, rue du Faubourg Saint-Antoine, Paris, IF 75012, FR.
-
How many shares of GSGTF are traded daily?
-
The average number of GSGTF shares traded daily for last 3 months was 6.
-
What is the market cap of GSGTF currently?
-
The market value of GSGTF currently stands at $14.67M with its latest stock price at $0.09